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Abstract: APOBEC is a mutagenic source in human papillomavirus (HPV)-mediated malignancies,
including HPV+ oropharyngeal squamous cell carcinoma (HPV + OPSCC), and in HPV genomes.
It is unknown why APOBEC mutations predominate in HPV + OPSCC, or if the APOBEC-induced
mutations observed in both human cancers and HPV genomes are directly linked. We performed
sequencing of host somatic exomes, transcriptomes, and HPV16 genomes from 79 HPV + OPSCC
samples, quantifying APOBEC mutational burden and activity in both host and virus. APOBEC
was the dominant mutational signature in somatic exomes. In viral genomes, there was a mean of
five (range 0–29) mutations per genome. The mean of APOBEC mutations in viral genomes was
one (range 0–5). Viral APOBEC mutations, compared to non-APOBEC mutations, were more likely
to be low-variant allele fraction mutations, suggesting that APOBEC mutagenesis actively occurrs
in viral genomes during infection. HPV16 APOBEC-induced mutation patterns in OPSCC were
similar to those previously observed in cervical samples. Paired host and viral analyses revealed
that APOBEC-enriched tumor samples had higher viral APOBEC mutation rates (p = 0.028), and
APOBEC-associated RNA editing (p = 0.008), supporting the concept that APOBEC mutagenesis in
host and viral genomes is directly linked and occurrs during infection. Using paired sequencing
of host somatic exomes, transcriptomes, and viral genomes, we demonstrated for the first-time
definitive evidence of concordance between tumor and viral APOBEC mutagenesis. This finding
provides a missing link connecting APOBEC mutagenesis in host and virus and supports a common
mechanism driving APOBEC dysregulation.
Keywords: APOBEC; HPV; Humanpapilloma virus; oropharyngeal cancer; oropharyngeal squamous
cell carcinoma
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1. Introduction
The apolipoprotein-B mRNA-editing catalytic polypeptide-like (APOBEC) 3 family
of cytidine deaminases is a major mutagenic source in human papillomavirus (HPV)-
mediated cancers, including cervical and oropharyngeal squamous cell carcinoma (HPV +
OPSCC) [1–5]. APOBEC-induced mutations constitute a high proportion of the somatic
mutations in HPV + OPSCCs and can result in driver mutations, such as activating muta-
tions in PIK3CA [3,6]. The underlying mechanisms driving APOBEC dysregulation and
mutagenesis in HPV + OPSCC, and other HPV-mediated cancers, are unknown. Since
APOBECs are viral restriction agents, it has been proposed that host genome mutations
may actually be “collateral damage” following APOBEC activation by viral infecton [7,8].
Following HPV infection, APOBEC is upregulated by HPV oncoproteins and by IFN
as part of the innate immune response, and this can inhibit HPV both directly, with the
cytidine deamination of viral DNA leading to degradation, and indirectly, by decreas-
ing HPV virion infectivity [9–12]. APOBEC-mediated mutational signatures have been
identified in both viral and cancer genomes. Viral editing is identifiable and reproducible
in vitro through APOBEC induction and in vivo in cervical pre-cancers and cancers [13–16].
APOBEC mutations are present in nearly all human cancers but are particularly promi-
nent in HPV + OPSCC, where they are associated with multiple measures of immune
upregulation [1,2,4,5,17–20].
We and others have shown that HPV lineages/sublineages and individual genetic
variants are associated with important differences in cervical carcinogenicity [21–35].
In particular, our group has published large case–control studies characterizing muta-
tions across cervical HPV16 genomes, utilizing an HPV whole genome sequencing (WGS)
approach. These studies demonstrated that benign or clearing HPV16 infections have
more genetic variants in specific viral regions than cervical precancers/cancers [34,36].
APOBEC-associated mutational signatures were also identified across the HPV16 genome
and associated with a significant reduction in the carcinogenicity of HPV16 [36]. Thus,
evidence supports the presence of APOBEC-induced mutations in both the genomes of
HPV-mediated cancers and in HPV itself; however, we do not know whether APOBEC
mutational activity in host and virus is directly linked. Here, using 79 HPV + OPSCC
samples with paired sequencing of host somatic exomes, transcriptomes, and viral whole
genomes, we apply computational approaches to characterize APOBEC activity in both
host and viral genomes.
2. Materials and Methods
2.1. Samples
A total of 79 HPV + OPSCC tissue and paired blood samples were identified through
existing databases at Vanderbilt University Medical Center and the University of Pittsburgh.
HPV status was determined by p16 staining and subsequently by WGS for the detection
of viral genomes. After the pathology review, DNA and RNA were extracted from FFPE
tissue blocks using Zymo Quick DNA and RNA FFPE kits. Of these, 18 samples had been
previously contributed to the Cancer Genome Atlas (TCGA) from the same institutions
and had pre-existing whole exome sequencing (WES) and RNA-Seq. For these cases, DNA
was extracted from FFPE blocks for viral WGS alone.
2.2. Sequencing
Somatic DNA underwent WES using the KAPA HyperPrep Library Preparation
Kit, followed by hybrid capture with the Illumina Rapid Capture Exome Enrichment
Kit. All sample pairs were validated with Fluidigm fingerprint data to confirm sample
identity and fidelity. The average (range) coverage was 218× (70–402×). Somatic RNA
underwent RNA-Seq using the Illumina TruSeq RNA Exome Kit. The average (range)
number of reads per samples was 151 M (17.5 M–333 M). HPV16 DNA underwent WGS as
previously described by custom AmpliSeqTM panels, followed by sequencing on an Ion
Torrent platform with average (range) coverage of 23,000× (1500×–56,000×) [37]. A total
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of 74 WES-seq, 68 RNA-seq, and 72 viral WGS samples passed quality control. Of these
samples, 63 had data available from all three platforms.
2.3. Informatics
Somatic datasets: Somatic SNVs were called using MuTect v1. Mutations were
screened against Panel of Normal (PoN) databases to remove common SNPs and re-
current sequencing artifacts. SNP-counting and copy number segmentation were carried
out using FACETS. SNP counts were generated with a minimum mapping quality of 15,
minimum base quality of 20, pseudo-spacing of 100 and a minimum read count of 25.
Copy number data were segmented using a window size of 1000, Variant Allele Fraction
(VAF) threshold of 0.3 and cval of 300. Allelic amplifications/deletions were defined as
regions of any size with rounded integer total copy number states above or below 2, respec-
tively. Somatic mutation lists were combined with mutations lists from the entire TCGA
cohort, and mutational signatures were deconvolved using NMF (K = 8), as described
previously [1,38]. The IFN-γ score was defined as the mean expression of six genes (IFNG,
IDO1, CXCL9, CXCL10, HLA-DRA and STAT1) as described previously [39]. The analysis
of the PI3K/AKT/mTOR pathway was conducted using a six major effector gene signature
(PI3K, AKT1, AKT2, AKT3, PTEN, and MTOR) as described previously [40], and further,
hotspot loci were examined in IGV. Significantly mutated genes were identified using
MutSig2CV, and significantly copy-number-altered genes were identified using GISTIC 2.0.
MutSig and GISTIC p values were combined using Fisher’s method to calculate a unified
p value per gene. Pathway enrichment scores were then calculated by combining unified
p values for genes in a pathway, also using Fisher’s method.
Viral datasets: All HPV16 WGS data were aligned to a consensus HPV16 sequence
NC_001526.4 from PaVE [41]. Position-wise base counts were obtained, and a major
haplotype was created by taking the most prevalent nucleotide at each position. These
haplotypes were fed into the multi-alignment tool MUSCLE, along with multiple refer-
ence builds for HPV16 (AF402678, AF472509, AF534061, AF536179, AF536180, AY686579,
HQ644236, HQ644257, HQ644298, K02718), and reference sequences for HPV35, HPV33,
and HPV18. The resulting alignment was fed into PhyML (run using TOPALi v2.5), as-
suming a transversion model and allowing for invariable sites and specifying a gamma
distribution. The resulting phylogenetic tree allowed for the sublineage assignment of
each sample by nearest distance to a reference sequence. All samples were realigned with
respect to their relative reference. Putative mutation sites were nominated by having a
minimum total coverage of 100, a minimum alternate allele fraction of 0.02, and minimum
alternate reads of 2. Putative mutations were anonymized and manually reviewed in IGV
alongside other samples aligned to the same reference to remove low-evidence mutations
and recurrent sequencing artifacts.
Viral APOBEC-induced mutations were identified as C->T and C->G mutations at
TCW motifs (W is A or T), as described previously [36]. To count the number of APOBEC
targetable sites, we first counted TCW motifs across the HPV16 genome for each reference
build and then the total number across all samples’ HPV16 genomes on their respec-
tive reference builds. Since there are three possible changes at each nucleotide position,
APOBEC-targetable sites were counted as one-third of the total number of TCW motifs.
Mutation rates were calculated as the total number of APOBEC mutations, divided by the
total number of APOBEC-targetable sites at the gene level and genome level, stratified
by mutation type (synonymous (S) and non-synonymous (NS)) and variant allele fraction
(VAF) (low-VAF (VAF ≤ 0.5) and high-VAF (VAF > 0.5)).
3. Results
A total of 79 HPV + OPSCC primary tumor samples were included in the analysis. The
average patient age was 55. A total of 82% of the cohort were male and 60% had a history of
tobacco exposure of >10 pack years. Somatic exomes were pooled with TCGA data and mu-
tational signatures extracted. As expected, HPV + OPSCC samples predominately clustered
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with other tumors dominated by the APOBEC mutational signature, with variable APOBEC
mutational burden between samples (Figure 1A,B, Supplemental Figure S1). PIK3CA
hotspot mutations, which have previously been described to be caused by APOBEC activity
in HPV + OPSCC, were exclusively associated with APOBEC enriched samples (Figure 1B).
The PI3K/AKT/mTOR pathway was disproportionately mutated across the cohort (p <
3.22 × 10−8) and amplifications in chromosomes arm 3q, which contains PIK3CA, were
present in 41 samples. Both of these alterations have previously been described to occur
frequently in HPV + OPSCC5. APOBEC mutations, A3A expression, and APOBEC RNA
editing, as measured by hotspot DDOST558C > U mutations, were weakly correlated,
consistent with prior reports, likely due to the episodic nature of APOBEC activity (Figure
1C) [42].
Figure 1. APOBEC is the dominant mutational signature in HPV + OPSCC. (A) Somatic mutation lists were combined with
all cancers in TCGA and mutational signatures were deciphered using NMF. Mutational patterns were then projected into
two-dimensional space with t-SNE. Head and neck squamous cell carcinoma tumors were colored in blue dots and HPV +
OPSCCs were highlighted with blue circles. (B) Mutational signatures ordered by APOBEC contribution (magenta) in HPV+
OPSCC samples. PIK3CA hotspot mutations, E542K and E545K, were exclusively detected within APOBEC-enriched (>25%;
dashed line box) tumors. (C) Weak correlations between APOBEC mutation burden and APOBEC3A (A3A) expression
(left) and A3A-associated RNA editing activity (right).
APOBEC mutations were annotated in the HPV16 genomes after first assigning each
viral genome to a sublineage. A1 (n = 45) was the predominant sublineage, followed by
A2 (n = 19), D3 (n = 4), A4 (n = 3) and C1 (n = 1). There was an average of five (range
0–29) mutations per viral genome. The mean APOBEC mutations in the viral genomes was
one (range 0–5), with an APOBEC to non-APOBEC mutation ratio mean of 1:5. Variants
were most heavily clustered in the E2 C-terminal DNA-binding domain (Q349E, S364C,
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S348C, E344Q), including in a position previously described [43] to impact transcription
and the replication of the viral genome (D338N) (Figure 2A,B and Supplemental Table S1).
There was no clear strand bias for HPV16 APOBEC mutations, suggesting that cytosines
on both strands of the viral DNA are vulnerable to attack by APOBEC, likely during
viral DNA replication, when both strands of viral DNA experience a single-stranded state.
This is similar to APOBEC mutations in human DNA, which are also observed on both
strands, but with a detectable bias toward the lagging-strand template, not observed here,
possibly due to a lack of power owing to low overall viral mutation counts [44]. APOBEC
mutations were found predominantly at very low and very high VAFs (Figure 2C,D).
Viral APOBEC mutations, compared to non-APOBEC mutations, were more likely to be
low-VAF mutations (occurring newly within the host), while non-APOBEC mutations
were more likely to be high-VAF (existing prior to infection of the current host), suggest-
ing that APOBEC mutagenesis actively occurrs in viral genomes during infection of the
current host. Viral APOBEC mutations had a higher nonsynonymous/synonymous ratio,
while non-APOBEC mutations showed the depletion of non-synonymous variants at high
VAFs compared to expectation, suggesting the influence of purifying selection (Figure 2E,
Supplemental Figure S2).
Figure 2. Mutation distributions in the viral and tumor genomes. (A) All viral mutations distributed across the genome
with APOBEC mutations colored in red and non-APOBEC mutations in blue. (B) Distribution of viral APOBEC mutations,
with positive strand mutations in purple and negative strands in green, highlighting enrichment of variants in E2. Viral
(C) and tumor (D) APOBEC and non-APOBEC mutations by variant allele fraction demonstrating predominance of
very low and very high VAF mutations in the viral genome. (E) Expected (blue and red lines) vs. actual (black dots)
nonsynonymous/synonymous ratio for APOBEC (red) and non-APOBEC (blue) mutations demonstrating higher non-
synonymous/synonymous ratios for APOBEC mutations and depletion of non-synonymous variants at high VAFs compared
to expected in non-APOBEC mutations, suggesting purifying selection.
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To assess the relationship between APOBEC mutations in the viral and host genomes,
samples were divided into APOBEC-low and -high mutational burden groupings based
on host somatic mutations (Figure 3A). APOBEC-high samples had higher viral APOBEC
mutation rates (p = 0.017; Figure 3B), and APOBEC mutagenesis in host and viral genomes
was positively correlated (ρ = 0.24, p = 0.056; Figure 3C). We further examined additional
measures of APOBEC activity in both tumor and virus and found similar trends for
APOBEC RNA editing at the DDOST hairpin hotspot (p = 0.008), A3A mRNA expression
(p = 0.14), and IFN-γ scores (p = 0.053), which are tied to APOBEC activity (Figure 3D–F).
Figure 3. APOBEC mutations are concordant between tumor and viral genomes. APOBEC (A) mutations in tumor genomes,
(B) mutations in the viral genome. (C) correlation between host and viral genomes, (D) RNA editing and (E) 3A gene
expression, demonstrating linkage between APOBEC activity in virus and host. (F) APOBEC-enriched subjects also had
higher IFN-γ scores, suggesting immune upregulation, possibly in response to viral infection.
4. Discussion
We conducted the first study to-date evaluating APOBEC-induced mutations in both
host and viral genomes, providing a missing link connecting APOBEC mutagenesis in host
and virus and supporting a common mechanism driving APOBEC dysregulation. Our
group previously characterized HPV16 APOBEC-induced mutations in over 5000 cervical
benign, pre-cancer and cancer samples, and identified low VAF mutations linked to benign
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or clearing infections [36]. We [36] and others [16] have suggested that the low VAF
viral mutations were likely induced during infection. Here, we characterized HPV16
APOBEC-induced mutations in HPV + OPSCCs using deep NGS and utilized the paired
sequencing of HPV16 and host somatic genomes to determine whether APOBEC activity
was concordant in host and viral genomes. We showed that OPSCC HPV16 APOBEC-
induced mutations occurred predominantly at low VAF, similar to what we observed in
cervical HPV16 genomes, and importantly, correlated them with host somatic mutations.
These data show that APOBEC mutates both cancer and viral genomes during an infection.
We identified APOBEC-signature mutations in OPSCC HPV16 genomes, which existed
at both very low (new within host mutations) and very high (old mutations carried from
prior host infections) VAFs. The OPSCC HPV16 APOBEC mutation patterns observed
were similar to those previously reported in cervical HPV16 genomes [36]. Viral APOBEC
mutations were most prominent at low VAFs, which is of interest as HPV genomes have
long been considered stable during persistent infection, yet these data suggest that APOBEC
editing of viral genomes is actively occurs during infection. This is despite the fact that
HPVs have evolved to have fewer APOBEC target sequence sites, likely in an effort to avoid
APOBEC restriction and thus viral damage and clearance [45]. This evolutionary pattern
also results in the enrichment of potential non-synonymous APOBEC mutations compared
to non-APOBEC mutations. In accordance with this, we observed a high nonsynonymous-
to-synonymous ratio for viral APOBEC mutations overall. The densest cluster of APOBEC
mutations occurred in E2 and included D338N, an HPV16 SNP that was previously reported
to reduce p53 binding [46]. Interestingly, D338N was also prevalent in cervical cancer
samples from our previous study. We also found a depletion of nonsynonymous high-VAF
mutations for non-APOBEC mutations, but did not observe this for APOBEC mutations.
This could suggest that some nonsynonymous viral APOBEC-induced mutations may
be beneficial to the virus and contribute to the evasion of host immunity by altering
viral antigens [7]. It is also possible that deleterious APOBEC mutations that result in
viral damage and clearance are simply not detected, as those viruses have already been
cleared during initial infection stages, leaving only viral genomes with a selective growth
advantage present in the cancer.
Importantly, we found that APOBEC-enriched somatic samples (greatest APOBEC
mutational burden and highest level of RNA editing) had higher viral APOBEC mutation
rates, providing direct evidence that APOBEC mutagenesis in host and viral genomes is
linked and occurs during infection. This suggests that in HPV-mediated cancers, the un-
derlying processes driving APOBEC dysregulation and resultant TCW context mutations
may be the same for both viral and somatic mutations. Mechanisms that drive APOBEC
mutagenesis in HPV + OPSCC, however, remain unknown. While APOBEC is known to
be activated by HPV oncoproteins, and through IFN signaling as part of innate immu-
nity/viral nucleic acid sensing, APOBEC mutations are prevalent in non-virally mediated
tumors, such as bladder, breast, and lung cancer, as well as non-HPV mediated head and
neck cancers, albeit to a lesser degree [1,2,20]. Thus, it is possible that both viral/innate
immunity and immune-independent processes, such as ssDNA targeting of the lagging
strand during replication stress or after double strand breaks, drive APOBEC expression in
HPV + OPSCC, and the high rates of APOBEC mutations in HPV + OPSCCs are a resultant
cumulative effect. This concept is supported by work from our group and others showing
multiple sources of APOBEC upregulation likely contribute to APOBEC mutagenesis in
HPV + OPSCC, including APOBEC germline polymorphisms and immune upregulation
in response to mutation-induced neoantigens [6].
In summary, we report the first study evaluating APOBEC mutagenesis in paired
human somatic and viral genomes, identifying the presence of APOBEC mutations in
OPSCC HPV genomes and concordance between APOBEC mutational burden within
virus and host during infection. These data provide a missing link connecting APOBEC
mutagenesis in host and virus and support a common mechanism driving APOBEC
dysregulation.
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Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/v13081666/s1, Figure S1: Mutational signatures ordered by APOBEC contribution, Figure S2:
Expected vs. actual nonsynonymous/synonymous ratio for APOBEC and non-APOBEC mutations
by viral gene. Table S1: HPV E2 APOBEC Mutations.
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